Today: 7 February 2026
Subscribe
Browse Category

NYSE:JNJ News 31 January 2026 - 7 February 2026

Johnson & Johnson stock rises on talc-court ruling — FDA Class I recall keeps JNJ in focus

Johnson & Johnson stock rises on talc-court ruling — FDA Class I recall keeps JNJ in focus

JNJ shares rose 0.9% to $239.99 in after-hours trading. A New Jersey appeals court barred Beasley Allen from representing plaintiffs in state talc cases against J&J, citing ethical concerns. The FDA announced a Class I recall for certain CEREPAK detachable coil systems sold by J&J’s MedTech unit, linked to four injuries and one death.
7 February 2026
····
Johnson & Johnson stock ticks up on talc-case ruling as FDA recall adds new wrinkle

Johnson & Johnson stock ticks up on talc-case ruling as FDA recall adds new wrinkle

A New Jersey appeals court barred Beasley Allen from representing plaintiffs in state talc lawsuits against Johnson & Johnson, prompting the firm to plan an appeal. J&J shares edged up 0.2% to $238.34 by midday. The FDA issued its most serious recall for certain CEREPAK detachable coil systems, citing risks of severe injury or death.
6 February 2026
·····
P&G stock price climbs in late trade as investors rotate to defensives — and an insider sale hits the tape

P&G stock price climbs in late trade as investors rotate to defensives — and an insider sale hits the tape

Procter & Gamble shares rose 1.1% to $158.61 in after-hours trading, outperforming broader market declines. CEO Ma. Fatima D. Francisco sold 8,000 shares at $158 each on Feb. 4, according to a regulatory filing. U.S. jobless claims increased to 231,000, while job openings fell to 6.542 million. P&G’s Gillette Venus announced a partnership with U.S. Figure Skating ahead of the Milano Cortina Winter Games.
6 February 2026
·····
JNJ stock rises as Johnson & Johnson takes talc shareholder fight to U.S. Supreme Court

JNJ stock rises as Johnson & Johnson takes talc shareholder fight to U.S. Supreme Court

Johnson & Johnson shares rose 1.3% to $237.59 after the company asked the U.S. Supreme Court to review a shareholder lawsuit over talc safety claims. The petition challenges a Third Circuit ruling on class certification standards. The case is separate from ongoing talc injury suits. Investors are also watching for new data on J&J’s atrial fibrillation devices at a cardiology event this week.
5 February 2026
····
Johnson & Johnson stock holds near highs as FDA flags Impella heart-pump issue — what to watch next

Johnson & Johnson stock holds near highs as FDA flags Impella heart-pump issue — what to watch next

The FDA issued an early alert on Abiomed Impella RP heart pumps, citing a pressure sensor defect linked to 22 serious injuries but no deaths. Johnson & Johnson shares rose 0.6% to $234.47, holding steady after hours. Traders await further FDA updates and MedTech data at the AF Symposium on Feb. 6. The S&P 500 fell 0.51% while the Dow gained 0.53%.
5 February 2026
·····
Johnson & Johnson stock price rises as RBC hikes target; JNJ data catalysts line up next

Johnson & Johnson stock price rises as RBC hikes target; JNJ data catalysts line up next

Johnson & Johnson shares rose 1% to $235.50 Wednesday, bucking a broader market decline. RBC raised its price target to $255, citing strong financials despite ongoing talc litigation. New data showed ERLEADA cut prostate cancer death risk by 51% versus darolutamide. Investors await updates at the AF Symposium on Feb. 6 and a TD Cowen event on March 3.
4 February 2026
·····
Johnson & Johnson stock price rises after RBC target hike as investors eye talc risk, new data

Johnson & Johnson stock price rises after RBC target hike as investors eye talc risk, new data

Johnson & Johnson shares rose about 1% Tuesday to $233.10 after RBC Capital Markets raised its price target, citing ongoing talc litigation risk. The company highlighted new real-world data showing ERLEADA cut death risk by 51% in certain prostate cancer patients. Investors await management’s next comments at the TD Cowen conference on March 3.
4 February 2026
····
Why Johnson & Johnson stock is up today: new Varipulse Plus update puts AFib data back in play

Why Johnson & Johnson stock is up today: new Varipulse Plus update puts AFib data back in play

Johnson & Johnson shares rose about 1.4% to $233.87 Tuesday after unveiling new pulsed-field ablation and imaging technologies ahead of the AF Symposium. The company will present Omny-AF pilot data on Feb. 6 and its stock will trade ex-dividend on Feb. 24. Medtronic announced a $585 million CathWorks acquisition as PFA competition intensifies.
3 February 2026
·····
Johnson & Johnson stock rises as new Erleada survival data lands

Johnson & Johnson stock rises as new Erleada survival data lands

Johnson & Johnson shares rose 0.8% to $229.09 midday after the company reported real-world data showing Erleada cut the risk of death by 51% over 24 months versus darolutamide in advanced prostate cancer. The move tracked broader U.S. market gains. Investors await further feedback from doctors and insurers, and key dates including a Feb. 24 ex-dividend.
2 February 2026
·····
Johnson & Johnson stock price: JNJ in focus after EU panel backs Akeega expansion

Johnson & Johnson stock price: JNJ in focus after EU panel backs Akeega expansion

Johnson & Johnson shares closed Friday nearly flat at $227.25 after EU advisers backed expanded use of its prostate cancer drug Akeega. The Committee for Medicinal Products for Human Use recommended approval for patients with BRCA1/2 mutations. The final decision rests with the European Commission. Traders are watching Monday’s open and upcoming U.S. economic data.
1 February 2026
·····
Johnson & Johnson stock: Talc-court twist and EU drug nod set up next week

Johnson & Johnson stock: Talc-court twist and EU drug nod set up next week

Johnson & Johnson shares slipped 3 cents to $227.25 Friday after a U.S. judge dismissed a fraud lawsuit over its talc bankruptcy strategy. The European Medicines Agency’s drug panel recommended expanding J&J’s AKEEGA use for certain prostate cancer patients. Investors await Monday’s trading for signs of shifts in sentiment on litigation and drug approvals.
31 January 2026
····
1 2 3 … 11

Stock Market Today

Amazon’s $200B AI Spending Jolt Spurs Stock Selloff as Big Tech Capex Nears $650B

Amazon’s $200B AI Spending Jolt Spurs Stock Selloff as Big Tech Capex Nears $650B

7 February 2026
Amazon shares fell Friday after the company announced a $200 billion AI infrastructure plan for 2026, exceeding analyst expectations and reviving investor concerns about profitability. Combined 2026 capex flagged by Amazon, Alphabet, Microsoft, and Meta now tops $630 billion. Nvidia, AMD, and Broadcom shares surged on the news, while software and data firms remained under pressure.
Nvidia stock jumps nearly 8% as Big Tech AI spending bets lift chipmakers and Dow tops 50,000

Nvidia stock jumps nearly 8% as Big Tech AI spending bets lift chipmakers and Dow tops 50,000

7 February 2026
Nvidia surged 7.8% Friday, leading a chip stock rally that pushed the Dow above 50,000 for the first time. The PHLX semiconductor index gained 5.7% as Advanced Micro Devices rose 8.3% and Broadcom 7.1%. Amazon fell 5.6% after projecting $200 billion in 2026 capital spending. Investors weighed a $600 billion AI infrastructure outlay against sharp losses in software shares.
Go toTop